The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions.
Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. ARDX, -3.17% rocketed 75.4% on heavy volume toward a 16-month high in premarket trading Thursday, after an advisory panel of the U.S. The technique has proven to be very useful for finding positive surprises.
- The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
- It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases.
- An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.
- These returns cover a period from January 1, 1988 through September 4, 2023.
- See which 3 stocks are most likely to make moves following their insider activities.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. According to 6 analysts, the average rating for ARDX stock is “Strong Buy.” The 12-month stock price forecast is $8.25, which is an increase of 102.21% from the latest price. Ardelyx Inc. shares soared more than 60% in after-hours trading Wednesday, after the company reported positive results for a study of a proposed drug. Ardelyx said a second Phase 3 study of tenapanor, a drug targeting irr…
How has ARDX performed historically compared to the market?
Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company’s product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program.
- There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
- The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
- At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
In addition to scoring higher than 99 percent of stocks in the Healthcare sector, ARDX’s 84 overall rating means the stock scores better than 84 of all stocks. Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARDX in relation to earlier this year. Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Cidara Therapeutics, and CymaBay Therapeutics.
We’d like to share more about how we work and what drives our day-to-day business. Compare
ARDX’s historical performance
against its industry peers and the overall market. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it airline stocks in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.
6 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Ardelyx in the last year. The consensus among Wall Street equities research analysts is that investors should “buy” ARDX shares. It engages in the research, development, and commercialization of medicine for the treatment reflexivity theory of cardiorenal diseases. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA. H.C. Wainwright analyst Ed Arce maintained a Buy rating on Ardelyx (ARDX – Research Report) today and set a price target of $9.00.
MarketWatch
Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Ardelyx stock rockets again on massive volume, after plans to launch IBS-C treatment announced
The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of ARDX stock can currently be purchased for approximately $4.08. Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise.
ARDX chart
See which 3 stocks are most likely to make moves following their insider activities. The company has a one-year high of $5.13 and a one-year low of $1.10. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. MarketRank is calculated as an average of available category scores, range bound market with extra weight given to analysis and valuation. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year. These returns cover a period from January 1, 1988 through September 4, 2023.
After Medivation, These 6 Biotech Stocks Could Be M&A Targets Next
Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat’s FREE daily newsletter. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
Research Report for ARDX
Shares of Ardelyx Inc. rocketed 75.4% on heavy volume toward a 16-month high in premarket trading Thursday, after an advisory panel of the U.S. Food and Drug Administration voted that benefits of the biopharmaceutical com… The 84 rating InvestorsObserver gives to Ardelyx Inc (ARDX) stock puts it near the top of the Healthcare sector.